Opinion|Videos|August 9, 2024
Real-World Evidence and Emerging Therapies in Lower-Risk MDS: Insights from EHA 2024
Key opinion leaders (KOLs) examine real-world evidence and draw on their clinical experiences to inform their practice, discussing real-world dose escalations and key insights gained from practical application.
Advertisement
Episodes in this series
- Focusing on real-world evidence (RWE), how do outcomes compare what’s seen in practice and how does that impact your choice of therapy?
- Real-world dose escalation and outcomes of luspatercept across all LOTs (
Patel K, et al. EHA 2024. Abstract P768. ) - IMerge study, PROs in heavily pre-treated patients with LR-MDS:
Sekeres MA, et al. Blood. 2023; 142 (suppl 1):6479. - Real World Data Replicates Medalist Study Results (
Komrokji RS et al. Blood 2022 )
- Real-world dose escalation and outcomes of luspatercept across all LOTs (
- Can each of you share any key takeaways or additional data updates surrounding lower-risk MDS presented at EHA 2024? (if time permits)
- Let’s discuss novel agents and/or combination strategies in LR-MDS through ongoing research that may shape the future treatment landscape.
- Luspatercept plus erythropoietin in LR-MDS:
Jonasova A, et al. EHA 2024. Abstract P1886 . - Luspatercept plus ESA combinations in LR-MDS:
Komrokji RS, et al. Blood Adv. 2023. - Ph 2 study, elritercept (KER-050):
Díez Campelo M, et al. EHA 2024. Abstract S183 .
- Luspatercept plus erythropoietin in LR-MDS:
Advertisement
Related to this article
Teclistamab plus talquetamab met the primary PFS end point and improved overall survival in relapsed/refractory multiple myeloma in MonumenTAL-6.
The FDA has granted priority review to a supplemental application for talazoparib plus enzalutamide in HRR-altered mCSPC.
Camizestrant plus a CDK4/6 inhibitor was approved in the European Union for ER-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation.
The FDA is reviewing data for daraxonrasib in previously treated pancreatic cancer under the Commissioner’s National Priority Voucher program.
Johannes Schetelig, MD, MSc, discusses phase 3 data for post-transplant cyclophosphamide vs ATLG as GVHD prophylaxis in hematologic malignancies.
Matthew Galsky, MD, discusses the FDA approval of perioperative pembrolizumab plus enfortumab vedotin in MIBC.
The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
A 3-year, $225K award will focus on improving quality of life for patients living with long-term effects of cancer treatment.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
2
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
3
Dr Galsky on Systemic Therapy Advances in Muscle-Invasive Bladder Cancer
4
Dr Patel on the Unmet Need in EGFR+ Transformed Small Cell Lung Cancer
5